TREATMENT ADHERENCE, TOLERABILITY AND SAFETY OF AYURVEDA THERAPEUTIC REGIMEN IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS- AN OPEN LABEL, OPD-BASED, MULTI-CENTER STUDY

CENTRAL COUNCIL FOR RESEARCH IN AYURVEDA SCIENCES0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•2.A diagnosis of RA according to the ACR 2010 Rheumatoid Arthritis Classification Criteria
•3.Patients who are not on any conventional medicines such as methotrexate, biological Agents, glucocorticoids, cloroquine, and DMARDs or any other traditiona medicine for RA in the last 3 months prior to the treatment period.
•4.Patients willing to give informed consent.

•History or current diagnosis of any other inflammatory arthritis such as psoriatic arthritis or ankylosing spondylitis, still’s disease, septic arthritis, gouty arthritis etc or a non-inflammatory type of arthritis (e.g. osteoarthritis ) or fibromyalgia.
•Severity score >5.1 on DAS 28-CRP.
•Patient taking participation in any other clinical trial or have participated in any clinical trial in last 3 months.
•Any other condition which the P.I.thinks may jeopardize the study.
•Uncontrolled HTN. ( >160/100)
•Uncontrolled DM (HbA1c >8.0).
•Co-morbid conditions such as past history of Cardiac Arrhythmia, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 3 months, Renal Dysfunction( defined as S. creatinine > 1.2 mg/dl, asthmatic and COPD patients or other concurrent severe disease.
•Participants with BMI <18 and >35.
•History of allergic response/hypersensitivity to trial formulation or its ingredients.

发起方

CENTRAL COUNCIL FOR RESEARCH IN AYURVEDA SCIENCES